Adir Et Compagnie

Marie-Claire Rettori

Pierre Renard

Daniel-Henri Caignard

Patrick Depreux

Daniel Lesieur

Gerard Adam

Genevieve Baziard-Mouysset

Marc Payard

Ange Mouithys-Mickalad

B Eatrice Guardiola-Lemaitre

Sallouma Younes

Youssef Labssita

Mark Millan

Bruno Pfeiffer

Marie-Claude Viaud

Sylvain Rault

Isabelle Lesieur

Adrian Newman-Tancredi

G Erard Adam

Max Robba

Thierry Taverne

Jean-Charles Lancelot

Hamid Ait Mansour

Raymond Houssin

Dominique Manechez

Elizabeth Scalbert

Pascal Carato

G Erald Guillaumet

Herv E Prunier

Jean-Paul Bonte

Geard Adam

Maria Anastassiadou

Saadia Danoun

Compound of formula (I): in which R is as defined in the description, as well as their isomers and their pharmaceutically acceptable acid additions salts. Medicinal products containing the same are useful as Imidazoline receptors ligand.

Imidazoline compounds

A compound of general formula (I): ##STR1## where A, X, R.sub.1, Y, n and Ar are defined in the description. Medicinal products containing the same are useful as D.sub.4 receptor Ligands.

Heterocyclic aminomethyl compounds

A compound selected from those of formula (I): ##STR1## where RA, RB, RC, RD, A, n, X, Y and Ar are defined in the description, and a medicinal product comprising the same for treating a mammal afflicted with a disease associated with sigma receptors.

Benzopyran derivatives

The invention relates to a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, X and n are as defined in the description, the optical isomers thereof, and the addition salts thereof with a pharmaceutically acceptable acid or base and medicinal product containing the same, useful for treating a mammal afflicted with a pathology associated with the sigma receptors.

Aminoalkyl benzoxazolinones and benzothiazolinones

Phenoyalkylpiperazine derivatives

The present invention relates to compounds of formula (I): ##STR1## wherein A, x, y, R.sub.1, R.sub.2 and R.sub.3 are as defined in the description. The compounds are useful for treating diseases requiring a selective serotonin reuptake site and 5-HT.sub.2c or 5-HT.sub.3 ligand.

Tricyclic oxime ethers

The invention relates to a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.2', R.sub.2', R.sub.2'', R.sub.3 and n are as defined in the description, an optical isomer, and an addition salt thereof with a pharmaceutically-acceptable acid or base, and medicinal product containing the same useful for treating a mammal afflicted with a disorder associated to 5-HT.sub.1A or 5-HT.sub.2C receptors.

Alkylaminoindane compounds

The invention relates to the compounds of formula (I): ##STR1## in which R.sub.1 and R.sup.2 are as defined in the description, the optical isomers thereof, and an addition salt thereof with a pharmaceutically-acceptable acid or base, and medicinal product useful for treating a mammal afflicted with a disease associated with sigma receptors.

Aminoalkyl benzothiazolinones

Growing community of inventors

Courbevoie, France

Marie-Claire Rettori